Questions discussed in this category
Would surgical margins, evidence of angiolymphatic spread, number of lymph nodes removed during surgery inform your decision?
How reliable is somatic testing to detect an underlying germline predisposition?
If serum markers were normal, how strongly do you consider 1 cycle of BEP for embryonal predominant pathology?
VIP can be considered, but given complex psychosocial issues and limited community cancer treatment resources, this question is being asked.
NCCN guidelines state check at baseline and then as clinically indicated. Some other sources state, can check prior to each cycle of BEP?
What ...
Given persistent embryonal histology on RPLND, do you favor observation or TIP/VIP? What do you use to guide your decision?
Would you have reservations in treating patients with breast, GI, or pelvic malignancies with radiation alone or concurrent chemoradiation?
GI work up negative. NGS cancer type and isochromosome 12p ordered and pending. Pathology at RPLND was negative for cancer.
1549314677144081386512532123121233412253119031032573817035
Papers discussed in this category
Journal of the National Cancer Institute, 2005-09-21
Eur. J. Cancer,
Br. J. Cancer, 2007 Jan 30
AJNR. American journal of neuroradiology, 1996-02
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016-02-01
Cancer, 2020 Mar 15
J Clin Oncol, 2021 Apr 06
The New England journal of medicine, 1981-09-24
Ann Intern Med,
Clinical cancer research : an official journal of the American Association for Cancer Research, 2008-01-15
Eur J Clin Pharmacol, 2001 Aug
JAMA Netw Open, 2021 Aug 02
J Clin Oncol, 2019 Jun 10